Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
74°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by TherapeuticsMD, Inc.
TherapeuticsMD Announces Second Quarter 2024 Financial Results
August 12, 2024
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces First Quarter 2024 Financial Results
May 10, 2024
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Full Year 2023 Financial Results
March 29, 2024
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Third Quarter 2023 Financial Results
November 14, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Second Quarter 2023 Financial Results
August 14, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces First Quarter 2023 Financial Results
May 15, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
April 07, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
January 03, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
December 04, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Third Quarter 2022 Financial Results
November 14, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Additional $7 Million Private Placement
October 31, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces $7 Million Private Placement
October 03, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
September 12, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Second Quarter 2022 Financial Results
August 15, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
August 08, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
August 01, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Expiration of Tender Offer
July 13, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
May 31, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
May 20, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces First Quarter 2022 Financial Results
May 16, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
May 10, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
April 14, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
December 10, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
December 08, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Third Quarter 2021 Financial Results
November 11, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
November 11, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
October 27, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
October 15, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month
September 02, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector
August 23, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
Tickers
TXMD
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.